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Adenovirus (Ad) replicative complexes form at discrete sites on the nuclear matrix (NM) via an interaction
mediated by the precursor of the terminal protein (pTP). The identities of cellular proteins involved in these
complexes have remained obscure. We present evidence that pTP binds to a multifunctional pyrimidine
biosynthesis enzyme found at replication domains on the NM. Far-Western blotting identified proteins of 150
and 240 kDa that had pTP binding activity. Amino acid sequencing of the 150-kDa band revealed sequence
identity to carbamyl phosphate synthetase I (CPS I) and a high degree of homology to the related trifunctional
enzyme known as CAD (for carbamyl phosphate synthetase, aspartate transcarbamylase, and dihydroorotase).
Western blotting with an antibody directed against CAD detected a 240-kDa band that comigrated with that
detected by pTP far-Western blotting. Binding experiments showed that a pTP-CAD complex was immuno-
precipitable from cell extracts in which pTP was expressed by a vaccinia virus recombinant. Additionally, in
vitro-translated epitope-tagged pTP and CAD were immunoprecipitable as a complex, indicating the occur-
rence of a protein-protein interaction. Confocal fluorescence microscopy of Ad-infected NM showed that pTP
and CAD colocalized in nuclear foci. Both pTP and CAD were confirmed to colocalize with active sites of
replication detected by bromodeoxyuridine incorporation. These data support the concept that the pTP-CAD
interaction may allow anchorage of Ad replication complexes in the proximity of required cellular factors and
may help to segregate replicated and unreplicated viral DNA.
Initiation of adenovirus (Ad) replication occurs via a protein
priming mechanism involving the precurser of the terminal
protein (pTP). The covalent addition of a dCMP residue to
pTP at serine 580 provides a 39 hydroxyl to stimulate DNA
chain extension (16, 18, 31). The Ad DNA polymerase and
pTP form a heterodimer which binds specifically to the Ad
origin of replication (62). Nuclear factors I (NFI) and III
(NFIII) further stimulate initiation by interacting with the
polymerase complex and the Ad origin DNA (18, 45). The Ad
DNA binding protein (DBP) serves to stabilize single-stranded
DNA (ssDNA) during replication (58). There is considerable
evidence that Ad replication complexes are bound to specific
sites on the nuclear matrix (NM) (7, 14, 49, 69). Attachment of
these complexes to the NM is mediated through the interaction
of pTP (1, 25, 26, 55). Interaction of pTP with the NM may also
enhance expression of the late genes (55). Subsequent to Ad
replication site formation via pTP, NFI is recruited to the same
location (8).
The NM is a highly complex fibrillar protein network which
is impervious to treatment with DNase and high salt or lithium-
3,5-diiodosalicylate (3, 4, 42). This nuclear infrastructure is
made up of lamin polymers, core filaments, and membrane-
associated proteins. The NM is known to organize genomic
DNA into looped domains via matrix attachment regions (9).
The enzymatic activities of transcription, mRNA splicing, and
DNA replication are localized to discrete sites on the NM (6,
12, 13, 50). In addition, there is evidence that DNA modifica-
tion and deoxynucleoside triphosphate (dNTP)-synthetic en-
zymes such as cytosine DNA methyltransferase and thymidine
kinase, respectively, are associated with NM compartments
(38, 39). The association of large multiprotein complexes of
dNTP-synthetic enzymes and replication proteins in eukary-
otes has been proposed previously (51). Evidence for the ex-
istence of such complexes is suggested by cosedimentation of
virus-encoded ribonucleotide reductase and thymidine kinase
activities with herpes simplex virus (HSV) Pol (30, 51). Ad and
other DNA virus proteins bind to the NM, presumably to
harness such cellular activities.
Spherical or doughnut-shaped domains of viral synthesis
occur early after Ad infection and are composed of overlap-
ping zones of transcription and replication. Microscopy has
demonstrated that these structures contain DBP which parti-
tions with ssDNA (12). Over the intermediate phase of infec-
tion, ssDNA storage zones form and are surrounded by pe-
ripheral replicative zones which continue to expand during
infection (14). Ad pTP and Pol can be detected in the dough-
nut-shaped peripheral zones, which contain double-stranded
DNA, but not in the DBP-containing ssDNA centers (44). It is
thought that the peripheral zones containing pTP represent
initiation whereas the DBP centers represent elongation (14).
The majority of cellular components participating in Ad rep-
lication centers have yet to be identified. Therefore, our ob-
jective was to identify the protein(s) to which pTP binds at
replication sites on the NM.
In this work, we have demonstrated by far-Western blotting
and coimmunoprecipitation that Ad pTP binds to the pyrimi-
dine biosynthesis enzyme known as CAD (for carbamyl phos-
phate synthetase [CPS; EC 6.3.5.5], aspartate transcarbamylase
[ATC; EC 2.1.3.2], and dihydroorotase [EC 3.5.2.3]). We
found that CAD colocalizes with pTP foci on the NM. Bro-
modeoxyuridine (BrdU) incorporation experiments have
shown that pTP-CAD foci colocalize with active Ad DNA
replication centers. These foci were numerous and often be-
came large and pleomorphic late in infection. We suggest that
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the pTP-CAD interaction may serve to anchor the viral ge-
nome in the proximity of factors required for replication.
MATERIALS AND METHODS
Cell lines, viruses, and antibodies. HeLa CCL-2 cells (American Type Tissue
Culture Collection, Rockville, Md.) were used for isolation of pTP binding
proteins derived from the NM. Cells were grown in monolayer cultures at 37°C
in Dulbecco’s modified Eagle’s medium (GIBCO, Gaithersburg, Md.) supple-
mented with 5% fetal bovine serum (FBS; HyClone Laboratories, Logan, Utah).
To prepare a pTP extract, HeLa cells were coinfected with vaccinia virus recom-
binants vvpTP1 and vvT7 at a multiplicity of infection of 10 (2, 27). Virus was
allowed to attach to the cells for 1 h. The infected cells were washed with
phosphate-buffered saline (PBS) and then overlayed with Dulbecco’s modified
Eagle’s medium containing 5% FBS. The cells were harvested at 20 h postinfec-
tion (p.i.). Ad infections of HeLa cells for indirect immunofluorescence experi-
ments were carried out for 15 or 20 h at a multiplicity of infection of 10.
The 3-1A polyclonal antibody recognizing pTP was raised against a carboxy-
terminal peptide (PEPPLPPGARPRRRC) and was used for Western blotting
and immunoprecipitations (25). A monoclonal antibody (IB6A8) raised against
purified pTP was used for immunofluorescence and immunoprecipitation exper-
iments (1). All Western blots were probed with alkaline phosphatase-conjugated
goat anti-rabbit immunoglobulin G (IgG) secondary antibody (Southern Bio-
technology Associates, Birmingham, Ala.) and developed with 4-nitroblue tetra-
zolium chloride and 5-bromo-4-chloro-3-indolylphosphate (BCIP) (2). The CAD
polyclonal antibody and the CAD ATC region-specific antibody were kindly
provided by David Evans (Wayne State University). A monoclonal antibody
directed against the FLAG epitope (DYKDDDDE) was purchased from Kodak
(New Haven, Conn.). Monoclonal 12CA5 antibody raised against the influenza
virus hemagglutinin (HA) epitope (YPYDVPDYA) was a generous gift from
Vincent Kidd (St. Judes Children’s Research Hospital). A monoclonal antibody
(Antibody-1) used to detect BrdU incorporation into viral replication sites was
purchased from Oncogene Science (Manhasset, N.Y.). Secondary antibodies
used for the immunofluoresence experiments were fluorescein isothiocyanate
(FITC)-conjugated goat anti-mouse and anti-rabbit and Texas red (TXRD)-
conjugated goat anti-mouse and anti-rabbit antibodies (Southern Biotechnology
Associates).
Preparation of NM. The protocol used for preparation of NM involved DNase
treatment of HeLa cell nuclei followed by high-salt extraction of soluble proteins
and chromatin, as previously described (1, 42). Digestion of the nuclei was
carried out at a concentration of 2.5 3 106 nuclei per ml in modified digestion
buffer (20 mM Tris-HCl [pH 7.4], 20 mM KCl, 70 mM NaCl, 10 mM MgCl2) with
1 mM phenylmethylsulfonyl fluoride (PMSF) for 10 min at room temperature, as
described by Angeletti and Engler (1) and by Mirkovitch et al. (42). The nuclear
pellet was recovered by centrifugation at 2,000 3 g and 4°C in a microcentrifuge
for 10 min. The nuclear pellet was then extracted with high-salt buffer (2 M NaCl,
20 mM HEPES [pH 7.4], 20 mM EDTA) for 5 min on ice. The insoluble NM
pellet was recovered by centrifugation at 2,000 3 g and 4°C for 4 min. The pellet
was then washed several times in digestion buffer and finally resuspended in 100
ml of buffer with 1 mM PMSF. The protein concentrations of the NM prepara-
tions were determined by the method of Bradford (using a kit from Bio-Rad
Laboratories, Hercules, Calif.) (11).
Preparation of whole-cell extracts, cytoplasmic extracts, and NME. One-
hundred-millimeter-diameter plates of HeLa cells that either were uninfected or
were coinfected with the vvpTP1 and vvT7 viruses (multiplicity of infection of 7
for each virus) were resuspended in hypotonic buffer (20 mM HEPES [pH 7.5],
5 mM KCl, 0.5 mM MgCl2, 0.5 mM dithiothreitol [DTT]) and allowed to swell
on ice for 15 min. The cells were lysed by 10 strokes of a tight-clearance Dounce
homogenizer. Preparation of the whole-cell extract was similar to preparation of
a nuclear extract except that the post-Dounce lysate was adjusted to 100 mM
NaCl and incubated on ice for 1 h (15). Soluble protein was recovered by
centrifugation at 15,000 3 g and 4°C for 10 min. Cytoplasmic supernatants were
recovered from nuclei immediately after Dounce homogenization by centrifuga-
tion at 2,000 3 g and 4°C for 10 min and clarified by an additional centrifugation
at 15,000 3 g and 4°C for 4 min (15).
NM extract (NME) was prepared by extraction of NM with 8 M urea (1, 5, 24).
First, the NM was washed in digestion buffer containing 1 mM PMSF. The NM
pellet was extracted with a threefold-volume equivalent of disassembly buffer [8
M urea, 20 mM 2-(N-morpholino)ethanesulfonic acid (MES; pH 6.6), 1 mM
EDTA, 0.1 mM MgCl2, 1% b-mercaptoethanol, 1 mM PMSF]. The collected
NME supernatant was then step dialyzed for 2 h in 1,000 volumes of the same
buffer with 4 M urea followed by successive 2-h dialysis steps in disassembly
buffer containing 2 M, 1 M, and then 0.1 M urea at 4°C. The final dialysis step
was in 1,000 volumes of buffer B (20 mM NaCl, 20 mM HEPES [pH 7.5], 5 mM
MgCl2, 1 mM DTT, and 1 mM 4-(2-aminoethyl)benzenesulfonylfluoride
(AEBSF; Calbiochem, La Jolla, Calif.) overnight at 4°C. The NME was clarified
by centrifugation at 15,000 3 g and 4°C for 4 min.
Complex release assay. Phosphorylation-dependent release of pTP-CAD com-
plexes was assayed by techniques described previously (1). Fifty micrograms of
pTP-NM was incubated with 3 mM ribo-ATP (rATP) in phosphorylation buffer
(30 mM NaCl, 15 mM Tris-HCl [pH 7.0], 3 mM MgCl2, and 1 mM DTT with 1
mM AEBSF) for 1 h at 25°C. Supernatants recovered by centrifugation were
resuspended in Laemmli buffer with 0.1% sodium dodecyl sulfate (SDS) (36).
Samples (either heated or unheated) were then electrophoresed on an SDS–8%
polyacrylamide gel. The protein was transferred to nitrocellulose and probed
with anti-pTP or anti-ATC (CAD) antibodies.
pTP far-Western assay. The pTP far-Western blotting experiment was per-
formed as previously described (1). Protein samples were heated in Laemmli
denaturing buffer and electrophoresed on an SDS–8% polyacrylamide gel (36).
The proteins separated by size in the gel were then transferred to nitrocellulose
and blocked against 5% dry milk protein in PBS. The blot was gently rocked at
4°C overnight with 1 mg of cytoplasmic extract from cells infected with vvpTP1
and vvT7 in 5 ml of PBS with 1% dry milk protein and 2 mM AEBSF. Negative-
control blots were probed with vvT7 cytoplasmic extract alone. The blot was
rinsed with PBS for 10 min at room temperature. The subsequent development
of the blot was performed in the same manner as a Western blot (2).
Fractionation of NM proteins. Eleven milligrams of NME isolated from un-
infected HeLa cell nuclei was diluted into Dignam buffer and passed over a 5-ml
P11 phosphocellulose column at a rate of 0.5 ml/min (21). The column was
washed with 10 volumes of buffer D (20 mM HEPES [pH 7.5], 20% glycerol, 100
mM KCl, 0.2 mM EDTA, 0.5 mM DTT, and 1 mM PMSF). Bound protein was
eluted with a linear KCl gradient, from 100 to 1,000 mM in buffer D, over 30
fractions of 1 ml each. Fractions which contained pTP binding activity were
detected by far-Western blotting. The pTP binding activity eluted between 640
and 700 mM KCl. Positive fractions 18 and 19 were pooled for amino acid
sequence analysis.
Amino acid sequence analysis. A total of 600 mg of protein from the fractions
positive for pTP binding (fractions 18 and 19) was separated by loading it in one
long slot of an SDS–8% polyacrylamide gel and subjecting it to electrophoresis.
The protein was then transferred to a polyvinylidene difluoride membrane (Bio-
Rad) (2, 41). The blot was rinsed with PBS three times. A strip was cut from the
blot and was developed for determination of pTP interaction as described for the
far-Western blot. The remaining section of the blot was rinsed with sterile
deionized H2O and stained for protein with Ponceau S (Sigma Chemical Co., St.
Louis, Mo.; final concentration, 0.5%) (2, 41). The bands reacting with pTP were
identified by lining up the two sections of the blot. The 150-kDa reactive band
was excised from the membrane for proteolytic digestion with endoproteinase
Lys-C, high-performance liquid chromatographic (HPLC) purification of the
resulting peptides, and amino acid sequence analysis (performed by Harvard
Microchem, Cambridge, Mass.). Two peaks from the HPLC purification, which
were designated p70 and p120, were subjected to amino acid sequencing.
PCR, cloning, and Northern blot analysis of CPS I in multiple cell lines.
Oligonucleotide primers were designed which reflected the amino acid sequence
of peptide p120 (RVSQEH; residues 1157 to 1162) except that third-base wobble
was introduced so that potential naturally occurring isomers would not be ex-
cluded. A downstream primer was chosen in a region which was well conserved
between CPS I and CAD (STGFKIP; residues 1352 to 1358). These primers were
synthesized as follows: 59 primer, 59-AGAGTTTCTCAGGA(A/G)CAT-39; and
39 primer, 59-GGG(T/G)ATCTTAAA(G/T)CC(A/T)GTG-39. With these prim-
ers, a 0.6-kb DNA fragment from the pDR2 HeLa cell cDNA plasmid library
(Clontech, Palo Alto, Calif.) was PCR amplified, using the Advantage amplifi-
cation kit (Clontech). The DNA fragment was cloned into the pGEM-T vector
by standard techniques (2). Sequence analysis and comparison of the clone to the
GenBank databases confirmed its identity as CPS I. The 0.6-kb fragment with
excised by ApaI-NotI digestion. Twenty-five nanograms of probe DNA was la-
beled with 20 mCi of [a-32P]dATP (3,000 Ci/mmol) by random hexamer labeling
(Boehringer Mannheim, Indianapolis, Ind.). The probe was then heat denatured
for 5 min at 100°C. To obtain a CPS I mRNA expression profile, multitissue and
multitumor blots (Clontech) were probed. The blots were incubated in Ex-
presshyb solution (Clontech) at 42°C for 2 h with agitation. Hybridization was
carried out at 42°C for 12 h with agitation. The blots were also probed with
b-actin as an internal standard. The Northern blots were then washed with 23
SSC (13 SSC is 0.15 M NaCl plus 0.015 M sodium citrate)–0.05% SDS for 40
min at 50°C followed by a wash with 0.13 SSC–0.1% SDS for 40 min at 50°C (2).
The dried blots were visualized with a model 860 Storm PhosphorImager (Mo-
lecular Dynamics, Sunnyvale, Calif.).
Plasmid constructs. The immunoprecipitation experiment (see Fig. 6B) was
conducted with epitope-tagged CAD and pTP proteins. Both epitope linkers
were designed to encode the Kozak consensus translational start sequence (AC
CATGG) to enhance initiation of translation (35). The predicted amino acid
sequence of the (His)7-HA linker is MGHHHHHHHVYPYDVPDYASLG. The
(His)7-HA linker was constructed using complementary oligonucleotides with
EcoRI and NotI sites on the ends as follows (with underlining indicating the start
site for translation of the modified gene): top strand, 59-AATTCGCGCACCA
TGGGGCACCATCACCATCACCATCACGTCTATCCTTATGACGTCCCT
GACTATGCCAGCCTGGGC-39; and bottom strand, 59-GGCCGCCCAGGC
TGGCATAGTCAGGGACGTCATAAGGATAGACGTGATGGTGATGGT
GATGGTGCCCCATGGTGCGCG-39. The top and bottom strands were mixed
in equimolar amounts, heated to 70°C for 10 min, and slowly cooled to room
temperature. The pcDNA3.11 plasmid (Invitrogen, San Diego, Calif.) was di-
gested with EcoRI and NotI (New England Biolabs, Beverly, Mass.) and gel
purified. The double-stranded linker was subcloned into pcDNA3.11. The full-
length human CAD cDNA was then excised from pfCAD6 by NotI-ApaI (New
England Biolabs) digestion (33). The CAD cDNA was then subcloned into the
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pcDNA3.11 clone containing the (His)7-HA tag. This construct was named
pcDNA-CAD. Similarly, a (His)7-FLAG epitope tag linker was designed as a
fusion to pTP. The predicted amino acid sequence of the (His)7-FLAG linker is
MGHHHHHHHDYKDDDD. The (His)7-FLAG linker was constructed with
HindIII and EcoRI sites on the ends as follows: top strand, 59-AGCTTGGCGCA
CCATGGGGCACCATCACCATCACCATCACGACTACAAGGACGACGA
TGoACG-39; and bottom strand, 59-AATTCGTCATCGTCGTCCTTGTAGT
CGTGATGGTGATGGTGATGGTGCCCCATGGTGCGCCA-39. The
pcDNA3.11 vector was digested with HindIII and BamHI and then gel purified.
Ad type 2 pTP was excised from pGEM-pTP by digestion with EcoRI and
BamHI (New England Biolabs), gel purified, and ligated to the (His)7-FLAG
double-stranded linker. The resultant product was subjected to HindIII-BamHI
digestion followed by ligation into the same sites in pcDNA3.11. The subsequent
clone was designated pcDNA-pTP.
Immunoprecipitations. Whole-cell extracts of cells expressing pTP were pre-
pared after a vvpTP1-vvT7 coinfection. Five micrograms of polyclonal antibody
to CAD was allowed to bind to a 70-ml bed volume of CL-4B protein A-
Sepharose in a 300-ml total volume of immunoprecipitation buffer (50 mM
HEPES [pH 7.5], 250 mM NaCl, 0.05% Nonidet P-40, 0.1% Triton X-100,
0.005% SDS, 10 mM NaPO4 [pH 7.0], 1 mM NaF, 1 mM AEBSF, and 0.5 mM
DTT) for 1 h at 25°C with rotation (2, 37). The beads were washed three times
with immunoprecipitation buffer and then resuspended in the same buffer. Fifty
micrograms of cell extract was then incubated with a 10-ml bed volume of beads
for 2 h at 4°C with rotation. As a negative control, lysates were incubated with
beads lacking antibody. Immunoprecipitates were washed three times with im-
munoprecipitation buffer prior to boiling of samples in Laemmli sample buffer
and loading them onto an SDS–8% polyacrylamide gel (36). The protein was
then transferred to nitrocellulose and probed with either pTP monoclonal anti-
body (IB6A8) or CAD polyclonal antibody.
The immunoprecipitations with in vitro-translated His-FLAG–pTP and His-
HA–CAD were done to further demonstrate a protein-protein interaction be-
tween pTP and CAD. In vitro translation labeling of each fusion protein was
performed in a 50-ml total volume with 2 mg of plasmid DNA in the presence of
40 mCi of [35S]methionine (10 mCi/mmol; Amersham) and the buffer specified by
the manufacturer of the TNT kit (Promega, Madison, Wis.). These immunopre-
cipitations were done with immunoprecipitation buffer (25 mM HEPES [pH 7.5],
300 mM NaCl, 1 mM EDTA, 0.05% Nonidet P-40, 1 mM AEBSF) as described
by Webster et al. (66). Monoclonal antibodies directed against either the FLAG
or the HA epitope were used in conjunction with Streptococcus protein G (Sig-
ma) to precipitate the immunocomplexes. Five microliters of each translation
product was incubated either alone or in combination in 300 ml of immunopre-
cipitation buffer containing protein G–anti-FLAG or –anti-HA antibody com-
plexes. Immunocomplexes were electrophoresed on an 8% polyacrylamide gel,
and bands were visualized with a model 860 Storm PhosphorImager (Molecular
Dynamics).
Retention of CAD on the NM. Five hundred micrograms of HeLa cell NM was
prepared. The NM pellet was successively extracted for 1 min with 1 M guani-
dinium hydrochloride (GnHCl; Sigma) in accordance with the protocol of Fred-
man and Engler (25). After each extraction, the NM pellet was recovered by
centrifugation at 15,000 3 g and the GnHCl was removed by washing the NM
with digestion buffer. After each of five washes, an aliquot was taken for analysis.
The protein concentration of each aliquot was measured by the Bradford assay
(11); this was followed by Western blot analysis of 20 mg of protein with antibody
raised against the CAD enzyme.
Immunofluoresence of in situ NM. HeLa cells were seeded on coverslips and
allowed to grow to 60% confluence. The cells were then infected with Ad type 2
at a multiplicity of infection of 10. At 15 or 20 h p.i., the cells were harvested,
extracted, and fixed in accordance with the protocol of Pombo et al. (50).
Infected cells were pulsed with 1 mM BrdU for 20 min prior to harvesting (48,
50). Adherent cells were washed with PBS. The cells on the coverslips were
immediately extracted in situ with 0.5% Triton X-100 in CSK buffer (10 mM
HEPES [pH 7.5], 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM PMSF).
The cells were rinsed with CSK buffer, incubated with 0.1-mg/ml DNase in CSK
buffer for 10 min at 25°C, and then extracted with 2 M NaCl in CSK buffer on ice
for 5 min. The remaining cells were fixed with 4% paraformaldehyde in CSK
buffer. Alternatively, cells were fixed after washing with 0.5% Triton X-100 prior
to DNase treatment; this protocol gave identical results. Coverslips were pre-
blocked with 5% FBS in PBS for 30 min. Primary antibodies to CAD or pTP
were diluted 1:50 and 1:25 for the anti-BrdU antibody in PBS with 1 mM PMSF.
Coverslips were inverted on individual beads of antibody solutions for 2 h at 4°C
and then rinsed in PBS for 10 min. Secondary antibodies bearing FITC or TXRD
were incubated in the same manner at dilutions of 1:100 each. Coverslips were
mounted in Vectashield antifade medium (Vector Laboratories, Burlingame,
Calif.). Optical sections of 0.5 mm in diameter were obtained with a model 2000
confocal microscope (Molecular Dynamics) equipped with a 1003 oil immersion
objective. Images were captured with a Silicon Graphics workstation and stored
as Adobe 3.0 files (Adobe Systems, Mountain View, Calif.). Alternatively, an
Olympus IX70 microscope with a 1003 objective, equipped with digital confocal
functions, was used. Images were captured with IPlab Spectrum software (Signal
Analytics, San Jose, Calif.), and digital sections (of 1 mm in thickness) were
obtained with the power microtome function. As negative controls, infected cells
were probed with secondary antibodies alone or uninfected cells were stained
with either polyclonal or monoclonal anti-pTP antibodies followed by secondary
antibodies. None of these showed a significant background (data not shown).
RESULTS
Isolation of pTP binding proteins in the NM. Ad DNA
replication sites occur in punctate foci in the nucleus (12, 50;
for a review, see reference 14). Previous work has also dem-
onstrated that pTP binds tightly to the NM, thereby anchoring
the Ad genome to a cytoskeleton-like structure in the nucleus
(25, 55). However, because of the insolubility and complexity
of this structure, little progress has been made in identifying
proteins that bind pTP in replication foci on the NM. In a
previous report, we described one approach to solubilizing this
structure: treatment of the NM with increasing concentrations
of rATP resulted in the release of pTP-NM protein complexes,
some of which were of very high molecular weight (MW) (1).
A second strategy for release of proteins from the NM is
extraction with 8 M urea. Urea extraction releases a large
number of proteins, including the nuclear lamins, which act
like intermediate filaments within the nucleus (24). The nu-
clear lamins can then be isolated by step dialysis against de-
creasing concentrations of urea; in low concentrations of urea,
the nuclear lamins form a precipitate that can be removed by
centrifugation (1, 24).
Using the portion of the extract that remains soluble after
step dialysis, we were able to employ phosphocellulose chro-
matography to further purify high-MW proteins which bound
to pTP. Protein fractions eluted from the P11 phosphocellu-
lose column were assayed for pTP binding by far-Western
blotting; fractions 18 and 19 showed two major bands in this
assay (Fig. 1A). As a negative control for the far-Western blot
assay, we used a cytoplasmic extract from HeLa cells that were
infected with a vaccinia virus-T7 recombinant that expressed
bacteriophage T7 RNA polymerase, rather than pTP; these
two high-MW protein bands were not detected when the load
material was probed with this cytoplasmic extract. The de-
tected nuclear polypeptides eluted from the column at between
640 and 700 mM KCl. The most-intense bands were at approx-
imately 240 and 150 kDa. However, a 120-kDa band and a
series of lower-MW bands were also detectable, all of which
are consistent with observations in our previous study (1).
Amino acid sequencing and analysis of peptides. From the
600 mg of protein present in P11 column fractions 18 and 19,
we were able to purify 32 pmol of the 150-kDa band; substan-
tially less of the 240-kDa protein was recovered. After endo-
proteinase Lys-C digestion and HPLC purification of the pep-
tide fragments of the 150-kDa protein, two peaks were chosen
for amino acid sequencing. Peptides designated p70 and p120
gave the following amino acid sequences: p70, FLEEAT-
RVSQEHPVVLT; and p120, EPLFGISTGNLITGLAAGA.
These sequences were compared to those of proteins in the
GenBank database by using the GCG software package (Ge-
netics Computer Group, Madison, Wis.) (Fig. 1B). Peptide
p120 was an exact match for CPS I (EC 6.3.4.16), while p70
differed from CPS I by only 2 residues. CPS I is a liver-specific
urea cycle enzyme (19, 28).
Northern blot analysis of CPS I tissue expression. Using
primers described in Materials and Methods, a DNA fragment
of 0.6 kb was amplified from the pDR2 HeLa cell cDNA
library. Blast searches done against the GenBank database
indicated that the 0.6-kb DNA fragment was CPS I. Multitissue
Northern blots were probed with the 0.6-kb CPS I fragment to
obtain a profile of CPS I expression. Normal tissues (spleen,
thymus, prostate, testis, ovary, small intestine, colon, and leu-
kocytes) expressed no detectable CPS I mRNA (data not
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shown). On a multitumor blot, we found that CPS I mRNA
was present only in HeLa cells (Fig. 2) and not in promyelo-
cytic leukemia (HL-60), mylogenous leukemia (K562), lym-
phoblastic leukemia (Molt4), Burkitt’s lymphoma (Raji), colo-
rectal carcinoma (SW480), lung carcinoma (A549), or
melanoma (G361) cells. This result is in agreement with pre-
vious work indicating that CPS I expression is extremely tissue
specific and is found only in hepatocytes and the intestinal
mucosa (19, 28).
Because the mRNA expression profile of CPS I did not
extend to tissues known to be permissive to Ad infection (such
as A549), we reasoned that CPS I itself may not be the NM
target for pTP binding. We therefore investigated the hypoth-
esis that the 240-kDa protein is the actual molecule to which
pTP binds during infection and that this protein exhibits ho-
mology to CPS I. Our homology searches had revealed that the
p70 and p120 peptides also exhibit significant similarity to a
240-kDa CPS I-related pyrimidine synthesis enzyme, CPS II,
also referred to as CAD (Fig. 1B). CAD contains a CPS do-
main which exhibits 50% identity and 70% similarity to CPS I
(57). CAD has a wide tissue expression profile and is required
for cell growth because it directly controls the synthesis of all
pyrimidines (61, 68). Therefore, we tested whether CAD was
present in NME from HeLa cells, whether it was released as a
complex with pTP from the NM, and whether it could bind
pTP in vitro.
Release of pTP-CAD complexes from the NM. Our previous
work demonstrated that a high-MW pTP-containing complex
was released from the insoluble NM by a mechanism that
requires ATP hydrolysis and that is inhibitable by compounds
known to inhibit tyrosine kinases (1). We therefore tested
whether rATP treatment might result in the release of pTP and
CAD from the NM as a detectable complex. We found that
like pTP, CAD was also released from the NM by rATP treat-
ment (Fig. 3A). Furthermore, under low-SDS conditions
(0.1%) without heating, a complex in excess of 300 kDa was
recognized by both anti-pTP (3-1A) and anti-CAD (specific for
the ATCase domain within CAD) antibodies. This complex ap-
peared to be very sensitive to proteolytic degradation, as indicated
by our detection of lower-MW forms (200 and 150 kDa) whose
relative abundance varied from experiment to experiment (data
not shown). These data are consistent with the formation of a
high-MW complex containing pTP and CAD.
pTP binds to an NM band that comigrates with the CAD
enzyme. Using a polyclonal antibody directed against CAD,
Western blotting was performed in tandem with the pTP far-
Western analysis against HeLa cell NME (Fig. 3B). The high-
est-MW band (240 kDa) identified by the pTP far-Western
analysis comigrated with the band detected by the CAD anti-
body. The lower-MW band that reacted with pTP is consistent
with a known CAD degradation product (23). A cytoplasmic
extract from vaccinia virus-T7-infected HeLa cells was used as
a negative control in these NME blotting experiments; this
control demonstrated that the pTP antibody did not nonspe-
cifically cross-react with NME protein. We concluded that the
CAD enzyme is present in NME and that it may represent the
pTP binding protein. Since CAD and CPS I show homology
FIG. 1. Fractionation of pTP binding proteins and amino acid sequencing.
(A) Eleven milligrams of NME was loaded onto a 5-ml P11 phosphocellulose
column. The retained protein was eluted with a linear KCl gradient of 100 to
1,000 mM. Twenty-microgram samples representing loaded NME (Load),
flowthrough (FT), or eluted fractions (17 to 21) were separated on an 8%
polyacrylamide gel and transferred to nitrocellulose. The blot was then probed
with a pTP cytoplasmic extract prepared from cells infected with a vaccinia virus
recombinant expressing pTP (vvpTP1). An identical blot of the loaded NME was
probed with a T7-vaccinia virus recombinant cytoplasmic extract (Negative Con-
trol). Two major bands, with molecular masses of 240 and 150 kDa, were
detected with pTP. The positions of molecular mass markers are shown to the
left (in kilodaltons). (B) Fractions 18 and 19 were pooled, electrophoresed in
batch, and blotted to a polyvinylidene difluoride membrane. The pTP-reactive
band of 150 kDa was excised and subjected to amino acid sequencing. The amino
acid sequences of two peptides (p70 and p120) obtained by endoproteinase
Lys-C digestion of the 150-kDa band were determined. The pileup of sequences
is the result of a Blast search of the GenBank database. Peptide p70 corre-
sponded to amino acids 1151 to 1167 of CPS I, and p120 corresponded to amino
acids 288 to 306 (left). The Blast search also revealed the homology of p70 and
p120 to the related CAD enzyme. Peptides p70 and p120 corresponded to amino
acid positions 1110 to 1126 and 246 to 264, respectively, of CAD (right).
FIG. 2. CPS I is expressed only in HeLa cells. A multitumor Northern blot
containing 2 mg of poly(A)1 mRNA per lane was probed with a 0.6-kb fragment
of the CPS I gene (nucleotides 3471 to 4077). The blot was hybridized at 42°C for
12 h. The lanes contained the following samples: promyelocytic leukemia (HL-
60), HeLa cell, mylogenous leukemia (K562), lymphoblastic leukemia (Molt4),
Burkitt’s lymphoma (Raji), colorectal carcinoma (SW480), lung carcinoma
(A549), and melanoma (G361). CPS I (6.0 kb) is indicated by the upper arrow.
The 2.0-kb (b-actin) internal control is indicated by the lower arrow. The posi-
tions of molecular size markers are shown to the left (in kilobases).
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only in the CPS domain, it is possible that the pTP binding site
lies in this domain.
CAD is retained on the NM. In earlier work, Fredman and
Engler (25) had demonstrated that pTP remained associated
with the NM despite repeated extraction with 1 M GnHCl. In
an effort to impose the same criteria on the CAD-NM associ-
ation, we successively extracted uninfected HeLa cell NM with
1 M GnHCl. Western blotting of the resulting protein fractions
was performed with antibody to CAD. As shown in Fig. 4,
CAD is retained on the NM after as many as five extractions
with 1 M GnHCl. These results are in agreement with the
GnHCl-resistant retention of viral proteins such as Ad pTP
and cytomegalovirus pp65 on the NM (25, 54). Mammalian
CAD is known to be present throughout the cell, including the
nuclear lamina and the nucleolus (17). There is also evidence
that the CAD equivalent in Saccharomyces cerevisiae, URA2, is
present in the nuclear structures (46). URA2 contains a puta-
tive tripartite nuclear localization signal which has significant
similarity to regions in the human CAD gene (47). Therefore,
the detection of CAD in the nucleus and in the GnHCl-resis-
tant NM was not surprising.
pTP and CAD form immunoprecipitable complexes. In an
effort to determine if pTP-CAD complexes form in vivo, im-
munoprecipitations were performed. Whole-cell lysates were
prepared from cells infected with a vaccinia virus recombinant
expressing pTP protein. The lysates were incubated with
CL-4B (protein A-Sepharose) beads to which the CAD anti-
body was or was not prebound. The immunoprecipitated com-
plexes were analyzed for both CAD and pTP by Western blot-
ting. Immunoprecipitation of CAD was clearly dependent on
the presence of CAD antibody, as shown in the left panel of
Fig. 5. No pTP was precipitated from the reaction mixture
containing CL-4B beads alone (right panel). However, pTP
coimmunoprecipitated with CAD in the presence of CAD an-
tibody. These results suggest that a pTP-CAD complex is
formed in cells expressing pTP.
Is the pTP-CAD complex formed by a direct or an indirect
interaction? To address this question, we constructed epitope-
tagged pTP and CAD open reading frames that could be tran-
scribed from a T7 promoter (Fig. 6A). In vitro-translated pTP
and CAD were mixed in equal amounts in immunoprecipita-
tion buffer with protein G-Sepharose beads with or without
antibodies directed against either influenza virus HA or the
FLAG epitope (Fig. 6B). In this experiment, the CAD fusion
was specifically precipitated by the anti-HA antibody and the
pTP fusion was precipitated by the anti-FLAG antibody. When
incubated together, pTP and CAD were coimmunoprecipi-
tated with either of the two antibodies. These results suggest
that there may be a direct interaction between pTP and CAD.
FIG. 3. The CAD enzyme comigrates with the 240-kDa NM band detected
by pTP far-Western blotting. (A) Thirty micrograms of supernatant from rATP-
treated pTP NM was either heated or not in the presence of Laemmli buffer with
0.1% SDS. Samples were applied to an SDS–8% polyacrylamide gel in duplicate.
The resultant halves of the blot were probed with either anti-pTP (apTP) or
anti-CAD (aATC) antibodies. The arrow to the right indicates the position of
the high-MW pTP- and CAD-containing complex. The positions of molecular
mass markers are shown to the left (in kilodaltons). (B) Thirty micrograms of
NME was separated on an SDS–8% polyacrylamide gel and blotted to nitrocel-
lulose. A portion of the blot was probed with anti-CAD antibody (aCAD West-
ern). The other lanes were probed with either pTP extract (pTP Far Western) or
T7-vaccinia virus cytoplasmic extract as a control for the far-Western blotting
(Negative Control). Far-western blot lanes were then developed to show the
presence of a pTP interaction with the polyclonal anti-pTP antibody (3-1A). The
arrow indicates the 240-kDa band detected by pTP which comigrates with CAD.
The positions of molecular mass markers are shown to the left (in kilodaltons).
FIG. 4. CAD is tightly associated with the NM. Each lane contains 20 mg of
uninfected-HeLa-cell NM which was washed with 1 M GnHCl for the number of
times indicated above the blot. The blotted protein was probed with anti-CAD
antibody raised against the ATC domain. On the left is indicated the position of
the 206-kDa molecular mass marker.
FIG. 5. CAD and pTP coimmunoprecipitate from HeLa cell extracts. Fifty
micrograms of whole-cell extract prepared from HeLa cells programmed to
express pTP was mixed with either protein A-Sepharose beads alone or beads to
which anti-CAD (aCAD) antibody was prebound (indicated by plus and minus
symbols). Duplicate immunoprecipitation reaction mixtures were applied to an
8% polyacrylamide gel. Protein blotted to nitrocellulose was probed with either
aCAD or antibody to pTP (apTP). The positions of molecular mass markers are
shown to the left of each blot (in kilodaltons).
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pTP and CAD colocalize in foci on the NM. The work of
Pombo et al. (50) and Bridge et al. (13) has demonstrated that
Ad replication foci form in a coordinated manner during in-
fection. Immunofluorescence experiments indicate that pTP,
Pol, DBP, and Ad DNA colocalize in early viral structures (13,
43, 50). By using confocal and digital sectioning techniques, we
visualized pTP sites on the NM with reference to CAD enzyme
(Fig. 7). A monoclonal antibody (IB6A8) was used to detect
pTP, and a rabbit polyclonal antibody directed at the ATC
domain of CAD was used; the use of this ATC-specific anti-
body eliminated the possibility of cross-reactivity with CPS I
present in the infected HeLa cells. Ad-infected cells, harvested
at 20 h p.i. and treated with DNase and 2 M NaCl, showed
obvious colocalization of pTP and CAD. Both pTP and CAD
displayed punctate as well as diffuse nucleoplasmic staining.
Negative controls (secondary antibodies alone or pTP antibody
against uninfected cells) showed no significant background
(data not shown). The pTP-CAD foci numbered from 2 to 20
in a given focal plane; these values are similar to the numbers
seen in other studies (50). The spherically shaped structures
had a diameter of 1 mm or less at 15 h p.i. and continued to
expand and change shape throughout infection. This size is
similar to the 1- to 2-mm-diameter prereplicative foci observed
in HSV type 1 (HSV-1)-infected cells (20). At 20 h p.i., pTP
and CAD colocalized in ring-like structures which are com-
pletely consistent with the morphology described by Pombo et
al. (50).
pTP-CAD foci colocalize with sites of active DNA replica-
tion. Other groups have previously demonstrated that pTP and
Pol are present at sites of active virus DNA replication (14, 44,
50). To determine whether our pTP-CAD foci colocalize with
sites of DNA synthesis, we pulsed Ad-infected cells with BrdU
(Fig. 8). Control samples in which the BrdU pulse was omitted
showed no staining when reacted with the monoclonal BrdU
antibody (data not shown). We observed ringed pTP foci which
colocalized and encircled sites of BrdU incorporation. This
phenomenon was observed in most of the infected cells and is
consistent with the morphology of Ad replication foci de-
scribed by Pombo et al. (50). We found that rings of CAD
surrounded sites of BrdU incorporation in Ad-infected cells in
a manner identical to that of pTP. These results strongly sup-
port the interpretation that NM-bound CAD colocalizes with
and anchors pTP at active sites of Ad DNA replication.
DISCUSSION
The NM network has been identified as a specialized cellular
microenvironment whose domains allow important activities
such as DNA replication and modification, transcription,
mRNA splicing, kinase activity, and dNTP synthesis (1, 6, 32,
38, 39, 48, 67). Several viruses (such as HSV, cytomegalovirus,
simian virus 40, Ad, human papillomavirus (HPV), and Ep-
stein-Barr virus (EBV) encode proteins that appear to bind to
the matrix (13, 29, 40, 54, 56, 60, 63); the activities of some of
these proteins promote the rearrangement of this structure
during the course of the infectious cycle (22). Additionally, we
have observed that HPV type 11 E1, E2, E6, and E7 proteins
all bind to the NM (59). Ad invades nuclear domains contain-
ing these activities in order to complete its replication program
and produce viral particles. For example, immunofluorescence
studies have demonstrated that pTP, Pol, DBP, and Ad DNA
all colocalize in discrete early viral structures (reviewed in
reference 14). The formation of Ad replication domains on the
FIG. 6. Coimmunoprecipitation of in vitro-translated pTP-CAD fusions. (A)
The diagram at the top represents the epitope-tagged constructs that were used.
The fusion proteins were cotranslationally labeled with [35S]methionine. (B) The
products were mixed with either protein G (Prot-G) alone or protein G pre-
bound with monoclonal antibody to HA (aHA) or FLAG (aFLAG). The com-
binations for each reaction are indicated above the gel (by plus and minus
symbols). The gel was visualized with a Storm PhosphorImager (Molecular
Dynamics). Immunoprecipitation of pTP and CAD proteins is indicated by the
arrows. The positions of molecular mass standards are shown to the left (in
kilodaltons).
FIG. 7. pTP and CAD colocalize in foci on the NM. HeLa cells were grown on coverslips and infected with Ad for 20 h. The cells were treated with DNase and
extracted with 2 M NaCl to create in situ NM. Double staining with anti-pTP monoclonal antibody (IB6A8) and anti-CAD polyclonal antibody specific for the ATC
domain was performed. (A) pTP was visualized with TXRD-conjugated goat anti-mouse antibody. (B) CAD was visualized with FITC-conjugated goat anti-rabbit
antibody. (C) Merged image of pTP and CAD staining.
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NM occurs through interactions between pTP and other nu-
clear proteins and was therefore the target of our efforts (25,
44, 55).
In this work, we have utilized a biochemical approach to
identify the nuclear protein(s) to which pTP binds during Ad
infection. The extreme insolubility of the NM proteins has
been an impediment to the identification of components of Ad
replication foci. We have circumvented this problem by gen-
erating a soluble NME from which nuclear proteins that bind
pTP can be identified. Three criteria had to be satisfied in this
identification: (i) the target pTP binding site on the NM should
be a preexisting component; previous evidence indicated that
viral replication proteins are targeted to preexisting NM do-
mains and can bind in the absence of a viral infection (7, 20,
40); (ii) the pTP binding protein should be expressed in cell
lines capable of supporting Ad infection; and (iii) the pTP
binding protein must be tightly bound to the NM and colocal-
ize with pTP. Based on these criteria, we have provided both
biochemical and microscopy experiments that suggest that Ad
pTP binds directly to the CAD pyrimidine synthesis enzyme at
the sites of active Ad DNA replication on the NM.
The Northern blot analysis of expression of CPS I by tissues
supports our conclusion that CPS I is not likely to be the NM
target of pTP binding; it is found only in HeLa cells and not in
any other cell line tested, including cells known to be permis-
sive to Ad, such as A549 (Fig. 2). In contrast, the CPS I-related
enzyme CAD is known to be expressed in the spleen, kidney,
heart, lung, brain, adrenal gland, muscle, small intestine, large
intestine, and testis (61, 68). In fact, the expression of CAD is
correlated with the rate of cell division; CAD levels are two- to
fivefold higher in tumor cells than in normal cells and are
almost nonexistent in quiescent cells (10, 68). This evidence,
coupled with the fact that CAD expression is essential for S
phase and is upregulated at the G1/S boundary by c-Myc (10),
makes CAD a logical target for pTP binding during Ad infec-
tion.
In further analyses, we were able release from the NM by
rATP treatment a complex that was recognized by both pTP
and CAD antibodies (Fig. 3A). This complex appeared to be
very labile in in vitro manipulations. Additionally, we found
that the CAD enzyme comigrated with the pTP binding pro-
tein detected by far-Western blotting (Fig. 3B). Immunopre-
cipitation experiments demonstrated that pTP and CAD inter-
act directly (Fig. 5 and 6). Also, the fact that CAD is tightly
bound to the NM after extraction with 1 M GnHCl (as is pTP
[25]) further qualifies CAD as a potential pTP binding site on
the NM (Fig. 4). The CAD enzyme satisfies our initial criteria
because it interacts and colocalizes with pTP and because it
remains tightly associated with the NM. However, we cannot
rule out the possibility that other proteins interact with pTP or
may be involved in the complex with CAD.
In addition to the in vitro biochemical methods used to show
a direct protein-protein interaction between CAD and pTP,
digital confocal fluorescence microscopy was used to show the
localization of CAD within the cell nucleus. That CAD was
found to be associated with the nucleus and the NM was not
unexpected. There is evidence that the yeast homolog of CAD,
URA2, is in the nucleus (46) and that it contains a tripartite
nuclear localization signal that is conserved in human CAD
(47). A study by Chaparian and Evans (17) also showed that
mammalian CAD was found in the nucleus. The fact that CAD
partitions with the NM may be the result of its high MW and/or
protein-protein interactions with other NM components.
By fluorescence microscopy, we found that CAD localization
coincided with that of pTP in in situ NM preparations (Fig. 7).
The size and distribution of our pTP-CAD foci are in agree-
FIG. 8. pTP and CAD colocalize with sites of active replication on the NM. Cells infected with Ad for 20 h were pulsed with BrdU for 20 min. Cells were double
stained either with anti-pTP polyclonal antibody (A) and anti-BrdU monoclonal antibody (B) or with anti-CAD polyclonal antibody (D) and anti-BrdU monoclonal
antibody (E). Polyclonal antibodies to the CAD ATC domain and pTP were reacted with FITC-conjugated goat anti-rabbit IgG, while the monoclonal antibody to BrdU
was detected with TXRD-conjugated goat anti-mouse IgG. (C) Merged image of pTP and BrdU staining. (F) Merged image of CAD and BrdU staining.
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ment with data from similar studies by others (8, 43, 50). We
observed that prior to 15 h p.i., pTP-CAD foci were punctate,
small (,1 mm in diameter), and spherical. However, from 15 to
20 h p.i., pTP-CAD foci expanded into large (.1-mm-diame-
ter) rings or perhaps hollow spheres (50). The observation of
pTP-CAD toroids at 20 h p.i. is consistent with other work
showing that peripheral zones are likely to be the sites of
initiation of replication while sites of elongation of viral DNA
are thought to be in the center of such structures (14). Accord-
ingly, we found that the highest concentration of BrdU was at
the centers of pTP-CAD rings (Fig. 8). All of these morpho-
logical characteristics are consistent with data from previous
work on Ad replication foci (14, 42). Further, the prereplica-
tive nuclear structures of HSV-1 have a distinct punctate struc-
ture similar to those described here (20, 40).
It is possible that CAD, pTP, and other Ad replication pro-
teins are part of a very large multienzyme complex associated
with the NM. The work of Ricigliano et al. (53) suggests that
DBP participates in the formation of a 650-kDa high-salt-
stable complex which retains DNA binding and kinase activi-
ties. Cellular proteins such as NFI can also be recruited into
Ad replication complexes (8). Cellular DNA replication com-
plexes are known to be large and to be associated in part with
the NM; for example, DNA polymerase a can be isolated from
the NM as a 100S to 150S megacomplex (64). Among herpes-
viruses, there is also evidence for the formation of a multien-
zyme complex containing HSV Pol, ribonucleotide reductase,
thymidine kinase, cellular dihydrofolate reductase, and nucle-
oside diphosphate kinase (30). These examples suggest that we
cannot rule out the possibility that pTP and CAD also partic-
ipate in a larger complex of enzymes. The purpose of such a
complex might be twofold: (i) to provide an anchoring point at
which to segregate replicated and unreplicated viral DNA
within the expanding domains; and (ii) to bring viral replica-
tion into proximity with dNTP-synthetic enzymes, either to
impose regulation upon them or to take advantage of nucleo-
tide channeling, as has been suggested by Panzeter and Ringer
(49). The possibility that dNTP-synthetic enzymes are physi-
cally linked with the replication machinery has been consid-
ered by others (30, 51, 52). It is also possible that pTP binds
other components of the NM in addition to CAD.
Recent efforts have defined ND-10 domains and their con-
stituent proteins (such as the promyelocytic leukemia antigen
[PML]) as sites of deposition of viral replicative proteins. In-
deed, there is evidence that HSV-1 UL29, Ad DBP, and EBV
EBNA-5 tend to be found adjacent to ND-10 (22, 40, 60). NM
antigens such as B23 may also colocalize with Ad replication
proteins (65). However, there is ample indication that ND-10
may not be the target of direct binding of pTP and perhaps
other viral proteins. For instance, during viral infection, PML
and SP100 are reorganized by the activity of the Ad E4 ORF3
protein and actually are ejected from sites where viral replica-
tion proteins are staged (22); redistribution of ND-10 proteins
can also be induced by gamma interferon (34). In our experi-
ments, we have not observed the colocalization of PML with
pTP, with CAD, or with sites of BrdU incorporation into virus
DNA during Ad infection (data not shown).
The use of NM domains for replication and other viral
processes is a common phenomenon among DNA viruses such
as HSV, simian virus 40, Ad, HPV, and possibly EBV (13, 40,
56, 60). There still remain many questions about how these
viruses utilize sites on the NM during their infectious cycles
and about the cellular factors required for viral replication.
Biochemical characterization of these factors will be easier as
new methods for disruption of the insoluble NM complex be-
come available. By using virus proteins as tools to identify
important NM domains, we may be able to understand the role
that these complex nuclear structures play in regulating impor-
tant viral and cellular processes.
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